Genolution

Genolution SG&A Expenses

The Selling, General & Administrative Expenses of Genolution (225220.KQ) as of Nov 11, 2026 is 4.29 B KRW. In the previous year, Selling, General & Administrative Expenses was 8.39 B KRW — a change of -48.92% (lower).

SG&A Expenses

4.29 BKRW

YoY

-48.92%

Last updated:

Selling, General & Administrative Expenses of Genolution is 2025 4.29 B KRW. Selling, General & Administrative Expenses of Genolution was 2024 8.39 B KRW. It decreases by -48.92% lower compared to the previous year.

The Genolution SG&A Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SG&A Expenses
Date
SG&A Expenses
Jan 1, 2018
1.58 B KRW
Jan 1, 2019
1.73 B KRW
Jan 1, 2020
8.36 B KRW
Jan 1, 2021
9.66 B KRW
Jan 1, 2022
9.21 B KRW
Jan 1, 2023
7.47 B KRW
Jan 1, 2024
8.39 B KRW
Jan 1, 2025
4.29 B KRW
The Genolution SG&A Expenses history
YEARSG&A ExpensesYoY
4.29 BKRW-48.92%
8.39 BKRW+12.37%
7.47 BKRW-18.91%
9.21 BKRW-4.66%
9.66 BKRW+15.59%
8.36 BKRW+383.58%
1.73 BKRW+9.54%
1.58 BKRW+45.42%
1.09 BKRW+6.38%
1.02 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Selling, General & Administrative Expenses of Genolution is 4.29 B KRW in 2025.

Selling, General & Administrative Expenses of Genolution changed from 8.39 B KRW to 4.29 B KRW, representing a -48.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Selling, General & Administrative Expenses Genolution since 2006 – with annual values, charts, and detailed analysis.

SG&A expenses include all non-production costs such as salaries, marketing, rent, and administrative overhead. They are a key component of operating expenses.

Selling, General & Administrative Expenses's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Selling, General & Administrative Expenses's Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genolution

All Key Metrics — Genolution